Page 34 - HP2017FIN4PRN.indd
P. 34

Micro Labs                                                                                                                            Hikma Pharmaceuticals







                          Micro Labs Limited is a multi-faceted healthcare organization with a                                                                  Hikma Pharmaceuticals PLC is a fast growing multinational
                          proficient marketing team, state-of-the-art manufacturing facilities                                                                   pharmaceutical group which was founded in 1978 in Jordan. Hikma
                          and R&D centres that are at par with international standards. All this,                                                               develops, manufactures and markets a broad range of both branded
                          robustly backed by a strong distribution network and path-breaking                                                                    and non-branded generic and in-licensed products. Hikma is
                          research work has placed us amongst India’s fast growing                                                                              committed to the highest quality manufacturing with multiple FDA
                          transnational healthcare organizations.                                                                                               approved facilities. Hikma operates in the US, Europe and across the
                                                                                                                                                                MENA region. Growth in MENA is driven by strong demographics
                          Ranking 10th among prescriptions and 20th in sales, Micro’s brand                                                                     and growing investment in healthcare. Hikma delivered 23% revenue
                          portfolio includes some of the topmost brands in various specialties                                                                  growth, underlying its strong financial record in 2013. Hikma is the
                          like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain,                                                                   fourth listed pharmaceutical company in the FTSE 250. As of Dec.
                          etc. Amidst our proud achievers is Dolo, an award-winning brand                                                                       2013 Hikma’s global team was made up of 7,067 employees.
                          highly prescribed for fever management.
                                                                                                                                                                Operations are in 27 manufacturing facilities in 11 countries - FDA
                          The company is also at the forefront in social contribution, striving to                                                              approved facilities in 5 countries with cost effective R&D and
                          be a model corporate citizen in terms of Environmental Protection &                                                                   manufacturing.
                          Social Initiatives with significant contributions in the areas of
                          education and health.                                                                                                                 Our strategy for growth is to strengthen our leading
                                                                                                                                                                position in the MENA region, develop our global product
                           Micro Labs is poised to achieve unparalleled status in the global                                                                    range in growing therapeutic areas, extend our reach and
                          pharmaceutical industry. Backed by a profound and resolute vision,                                                                    diversity as partner of choice in the MENA region,
                          we now have our eyes set on attaining the $1 billion mark by 2015.                                                                    increase the scale of our specialty injectables business,
                                                                                                                                                                leverage our expertise and
                                                                                                                                                                capacity in the US
                                                                                                                                                                market, build on our
                                                                                                                                                                world-class
                                                                                                                                                                manufacturing and API
                                                                                                                                                                sourcing capabilities.
   29   30   31   32   33   34   35   36   37   38   39